Columbia School of Medicine, University of Missouri, Columbia, Missouri.
Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri.
J Cutan Pathol. 2020 Aug;47(8):742-746. doi: 10.1111/cup.13687. Epub 2020 Apr 29.
Checkpoint inhibitors have been revolutionary in the treatment of metastatic melanoma, non-small-cell lung cancer, and renal cell carcinoma. By restricting negative feedback of T-cells, checkpoint inhibitors allow the immune system to identify and destroy malignant cells. This enhanced immune response is efficacious in the treatment of the aforementioned malignancies; however, it may lead to immune-related adverse events. Bullous pemphigoid (BP) is a well-documented cutaneous adverse reaction of checkpoint inhibitors, with a majority of cases reporting an eosinophil-predominant or mixed inflammatory infiltrate. We report two cases of neutrophil-predominant BP presenting in patients on checkpoint inhibitors.
检查点抑制剂在治疗转移性黑色素瘤、非小细胞肺癌和肾细胞癌方面具有革命性意义。通过限制 T 细胞的负反馈，检查点抑制剂使免疫系统能够识别和破坏恶性细胞。这种增强的免疫反应在治疗上述恶性肿瘤方面是有效的；然而，它可能导致免疫相关的不良反应。大疱性类天疱疮 (BP) 是检查点抑制剂的一种有充分文献记载的皮肤不良反应，大多数病例报告以嗜酸性粒细胞为主或混合性炎症浸润。我们报告了两例中性粒细胞为主的 BP 病例，这些患者正在接受检查点抑制剂治疗。
